Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
5. Organogenesis launches PuraPly antimicrobial clinical program
Organogenesis said today that it launched its PuraPly Antimicrobial clinical research program, which will evaluate patients treated with PuraPly AM for up to 12 weeks. The 1st studies have started enrolling patients, according to Organogenesis.
The Canton, Mass.-based company’s PuraPly AM is a 510(k)-cleared device indicated for the management of acute and chronic wounds. The device is made of a bi-layered purified Type I collagen sheet, loaded with a broad spectrum antimicrobial agent that acts as a barrier against microbial colonization within wound dressings. Read more
4. Stryker’s touch-screen tablet drops for SurgiCount safety sponge
Stryker said today that it’s releasing a touch-screen table for its SurgiCount safety sponge, which is designed to prevent the “never event” of retained surgical items.
The SurgiCount system’s sponges and towels use unique identifiers so that healthcare providers can track them throughout a procedure, in real time; the system’s software creates a permanent record of each verified count. Stryker paid $120 million for Patient Safety Technologies, which developed the system, in March 2014. Read more
3. Cardiologist Dr. Kereiakes: the Synergy bioabsorbable stent boasts flexibility & safety
Dr. Dean Kereiakes knows a thing or 2 about coronary stents – he’s been a principal investigator in a number of clinical trials evaluating coronary stents over the past 20 years. So it counts when Kereiakes names the Synergy stent made by Boston Scientific‘s “the safest stent yet.”
An interventional cardiologist at the Christ Hospital, he was also a principal investigator in Boston Scientific’s 1,684-patient Evolve II trial, comparing the Synergy bioresorbable-polymer stent with the Promus Element Plus device. The study’s primary endpoint was target lesion failure at 12 months. Read more
2. Value-based healthcare: Evolent, Advisory Board mull merger
Evolent Health and the Advisory Board Co., which helped launch Evolent in 2011, are contemplating a merger, “people familiar with the matter” told Reuters.
Evolent, which makes software for hospitals moving from fee-for-service to an outcomes-based business model, was founded in 2011 by its top 2 investors, the University of Pittsburgh Medical Center Advisory Board Co., a healthcare research firm. Read more
1. Alere gains on judge’s dissent in different case
Shares in Alere closed up more than 3% last week as investors reportedly reacted to a Delaware state judge’s dissent in an unrelated case.
Investors in the diagnostics giant, which is fighting an attempt by Abbott to spike their $6 billion merger, viewed a dissenting opinion in a case involving a different deal as a good sign. In that case, Williams Co. vs. Energy Transfer Equity, Delaware Supreme Court Chief Justice Leo Strine Jr. dissented with the high court’s decision that ETE had the right to spike the deal; the Delaware Chancery Court magistrate in the original Williams ruling, Judge Sam Glasscock, is also overseeing the arbitration between Abbott and Alere. Read more
The post MassDevice.com +5 | The top 5 medtech stories for March 27, 2017 appeared first on MassDevice.
from MassDevice http://ift.tt/2naIQ38
Cap comentari:
Publica un comentari a l'entrada